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124 Poster Session IIrapamycin, and TGF- b on human Treg cell generation ex vivo.
Normal donor CD4 T cells were isolated by CD4 positive selection
and CD41CD127- cells were isolated by CD127 negative selection
and CD4 positive selection. Relative to total CD4 T cells,
CD41CD127- cells were enriched for the Treg transcription fac-
tor, Foxp3 (n5 8 experiments; P5 0.042); and also had reduced se-
cretion of IL-2 (P5 0.05) and IFN-g (P5 0.03). Both subsets were
expanded using anti-CD3, anti-CD28 co-stimulation and IL-2 6
rapamycin and 6 TGF-b. Relative to culture input of total CD4
cells, input of CD41CD127- cells were potent suppressors at day
12, asmeasured by inhibition of responderT cell proliferation in re-
sponse to allogeneic dendritic cell (DC) stimulation. The enhanced
capacity of CD127 negative selection to generate Tregs occurred
whether expansion was performed in rapamycin (P 5 0.02), TGF-
b (P 5 0.02), or combination of both (P 5 0.01). CD127 negative
selection alone (without rapamycin or TGF-b) was not sufficient
to generate Treg cells, as the resultant product secreted high levels
of IL-2 and IFN-g. In contrast, addition of rapamycin or TGF-b,
and in particular the combination, resulted in a Treg phenotype
as defined by: (1) high Foxp3 expression (50% CD41Foxp31);
(2) reduced Th1 cytokine secretion; and (3) suppressor function in
the allo-MLR. Transwell showed that expanded Treg cell suppres-
sionwas contact dependent.We hypothesized that such suppression
was mediated via modulation of DC function; to address this, Treg
cells and DC were co-cultured, and purified ‘‘conditioned’’ DC
were utilized as the APC source in allo-MLR. Indeed, DC condi-
tioned by Treg cells generated from CD41CD127- enriched cells
and expanded in rapamycin and TGF-b had: (1) significantly re-
duced secretion of IL-6 and TNF-a; (2) increased expression of
the inhibitory molecule PDL1; and (3) greatly reduced allostimula-
tory function; importantly, antibody blockade of DC expression of
PDL1 partially reversed the suppressive DC phenotype. In conclu-
sion, CD127- selction combined with ex vivo expansion in rapamy-
cin and TGF-b generates human Treg cells that inhibit
alloreactivity by modulating DC function. Adotive transfer of
such Tregs has implications in preventing GVHD after haemato-
poietic stem cell transplantation.337
THE PREDICTIVE VALUE OF GENE EXPRESSION PROFILES FOR ACUTE
GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION WITH NONMYELOABLATIVE CONDITIONING FOR HEMA-
TOLOGICAL MALIGNANCY
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Kornblit, B.1, Winther, O.2, Nielsen, F.C.3, Vindelov, L.L.1. 1Allogeneic
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Purpose:To test the hypothesis that global gene expression pro-
files of peripheral bloodmononuclear cells (PBMNC) day114 after
hematopoietic cell transplantation with nonmyeloablative condi-
tioning could predict the later occurrence of acute graft-versus-
host disease (GVHD) grade II-IV. Material: Between March 2000
and Marts 2006, 100 patients with hematological malignancies re-
ceived peripheral blood stem cells from an human leukocyte antigen
identical sibling/mother donor or from a matched unrelated donor
following nonmyeloablative conditioning with low dose fludarabine
and 2Gy of total body irradiation. Post-transplant immunosuppres-
sion consisted of cyclosporine and mycophenolate mofetil. Only
patients with sustained engraftment, who did not experience late-
onset acute GVHD after day 1100 were included; eight patients
were excluded due to graft rejection, three patients due to subopti-
mal RNA or lacking PBMNC samples, and further 15 patients due
to late-onset acute GVHD. Seventy-four patients were then eligible
for microarray analysis.Methods: RNA was precipitated from fro-
zen PBMNC from day114 post-transplant and gene profiling anal-
yses were performed using Human Genome U133 Plus 2.0
GeneChip Array. The array data were normalized, RMA modeled
and asinh transformed in R. The differentially regulated gene ex-
pression between the group of patients developing acute GVHD
before day140,156 and184 post-transplant compared to the pa-
tients never experiencing acute GVHD was identified and formed
the basis for the subsequent principal component analysis (PCA)and classifying models. No patients experienced acute GVHD be-
tween day185 and1100 post-transplant.Results:The patients ex-
periencing acute GVHD by different time points were separated
from the patients never experiencing acute GVHD by the PCA
plot. Furthermore, the best classifying models could separate the
groups correctly in up to 98% of cases. In addition, differentially
regulated genes between the two groups were identified. Conclu-
sion:These data suggest that the pattern of gene expression profiles
early post-transplant is able to predict patients with a high risk of
later occurrence of acute GVHD from those never experiencing
acute GVHD. This knowledge could be exploited to increase the
immunosupression and thus prevent acute GVHD in patients at
risk. Furthermore, candidate genes of interest for the pathogenesis
of acute GVHD have been identified.338
T CELL RECEPTOR GENE TRANSFER TO VIRUS-SPECIFIC T CELLS FOR
CELLULAR ANTI-TUMOR IMMUNOTHERAPY
van Loenen, M.M., Griffioen, M., van Egmond, H.M.E.,
Hagedoorn, R.S., Kester, M., Willemze, R., Falkenburg, J.H.F.,
Heemskerk,M.H.M. Leiden UniversityMedical Center, Leiden, Nether-
lands.
T cell receptor (TCR) transfer to engineer tumor specific T cells
may be an alternative strategy for adoptive immunotherapy. For
complete eradication of leukemic cells and to achieve long-term
protection, potent effector T cell function and long-termT cell per-
sistence are necessary. Therefore, we propose to use virus specific T
cells for TCR transfer since such engineered dual specific T cells
can be triggered via their endogenous TCR by latent presence of vi-
ral antigens, improving their long-term persistence. We previously
demonstrated that transfer of the minor histocompatibility antigen
HA-1 and HA-2 TCRs to CMV specific T cells led to the genera-
tion of anti-leukemic T cells with dual specificity. Based on these re-
sults, we developed a clinical grade method for generation of TCR
transferred virus T cells for cellular immunotherapy. Pentamers
combined with clinical grade available anti-biotin magnetic beads
were used to isolate CMV and EBV specific T cells. At day 3 after
isolation, T cells were transduced with multi-cistronic retroviral
vectors encoding the alpha and beta chains of the HA-2TCR linked
by an IRES or 2A-like sequence. Isolation by pentamer-coated
beads led to the generation of T cell lines with high frequencies
(.80%) of virus-specific T cells with 20–40% transduced cells.
The T cells exhibited dual specificity, and tetramer staining corre-
lated with lysis of target cells expressing endogenously-processed
HA-2. We determined whether these cells preserve their dual spec-
ificity upon repetitive stimulation. When frequent encounter of vi-
ral antigens leads to selective survival of TCR transferred T cells
predominantly expressing the CMVTCR incapable of proliferating
via the introduced TCR, persistence in vivo of TCR transferred
CMV T cells capable of controlling minimal residual disease may
fall short. We analyzed the TCR expression and functional activity
of the TCR transferred T cells after repetitive stimulation with
CMV or HA-2. TCR-transferred T cells repetitively stimulated
skewed to T cells predominantly expressing one TCR. However,
this skewing was not due to selective outgrowth, but to change of
TCR make up. This TCR make up appeared to be reversible, and
HA-2 TCR transferred CMV T cells remained their functional ac-
tivity via both TCRs after repetitive stimulation. In a clinical phase
I/II study, the safety, clinical and immunological efficacy of TCR-
transduced virus T cells as cellular anti-tumor immunotherapy
will be investigated.339
INFLIXIMAB COMBINED WITH DACLIZUMAB RESULTS IN A HIGH COM-
PLETE RESPONSE RATE WHEN USED TO TREAT ACUTE STEROID RE-
FRACTORY GRAFT-VERSUS-HOST DISEASE (SR-GVHD)
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